Labcorp Oncology Medical Affairs team: Unlocking the power of precision medicine through education, research and innovation
Welcome to a snapshot of our medical affairs team's dynamic engagement and impactful contributions in oncology. As we delve into the latest advancements and emerging trends, we're thrilled to share with you key highlights from the year.
By the Numbers
Team Highlights
In Oncology and Therapy, Mary Nesline, Senior Director of Clinical Evidence Development, published that negative SGT for patients with NSCLC done prior to CGP doubled subsequent CGP test cancelations because of tissue insufficiency and increased CGP DNA extraction failures.
For patients with NSCLC, tissue samples for testing are usually obtained through small biopsies. The standard of care for all patients with NSCLC is to evaluate for >10 biomarkers so oncologists can recommend targeted, personalized therapies. If only SGTs are ordered, then it is unlikely that a patient will have all biomarkers tested, and they may not be able to get a second biopsy for comprehensive testing. Furthermore, doing single gene tests before comprehensive profiling creates longer wait times for results, and this can be problematic when selecting optimal treatment for patients with cancer.
To provide NSCLC patients with testing for all recommended biomarkers, CGP is highly recommended to be performed first.
EXPLORE NOW
Through the Lens - Coming Soon
Explore the ever-evolving world of cancer care in our insightful content series, Through the Lens as we delve into the latest advancements in oncology diagnostics and their impact on patient outcomes. Each episode brings together leading oncology experts to discuss:
• Groundbreaking research: Uncovering the cutting-edge science shaping the future of cancer treatment
• Practical applications: Learning how precision medicine translates from lab to the clinic
• Real-world challenges: Exploring the hurdles faced in oncology care and discovering potential solutions
More than just information, this series fosters collaboration and unbiased education. Through the Lens not only empowers healthcare professionals and researchers but also patients to stay informed, inspired and at the forefront of medical oncology.
In Case you missed it
Featured Oncology Webinars
We are committed to continuous education and keeping you up to date about emerging biomarkers and best practices. In case you missed any of them, here is a snapshot of webinars presented this year. Our internal subject matter experts and thought leaders provide insights into targetable biomarkers and foster meaningful discussions with patients, oncologists and pathologists. We are proud to have created a virtual learning space where you can learn more at your pace within your own space.
In Case you missed it
Highlights from peer-reviewed manuscripts
We are focused on innovation and advancing scientific discovery. We are working hard to publish on a diverse range of topics that we believe will improve your clinical practice. Here is a snapshot of four high-impact manuscripts with links to the full text and graphical one-page summaries for your review.
Manuscript - 14 February 2024
Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer
Manuscript - 12 February 2024
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
Manuscript - 30 January 2024
LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
Our team in action
